NK cell cytotoxicity is controlled by numerous NK inhibitory and activating receptors. Most of the inhibitory receptors bind MHC class I proteins and are expressed in a variegated fashion. It was recently shown that TIGIT, a new protein expressed by T and NK cells binds to PVR and PVR-like receptors and inhibits T cell activity indirectly through the manipulation of DC activity. Here, we show that TIGIT is expressed by all human NK cells, that it binds PVR and PVRL2 but not PVRL3 and that it inhibits NK cytotoxicity directly through its ITIM. Finally, we show that TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytoxicity thus providing an ''alternative self'' mechanism for MHC class I inhibition.
NK cell cytotoxicity is controlled by numerous NK inhibitory and activating receptors. Most of the inhibitory receptors bind MHC class I proteins and are expressed in a variegated fashion. It was recently shown that TIGIT, a new protein expressed by T and NK cells binds to PVR and PVR-like receptors and inhibits T cell activity indirectly through the manipulation of DC activity. Here, we show that TIGIT is expressed by all human NK cells, that it binds PVR and PVRL2 but not PVRL3 and that it inhibits NK cytotoxicity directly through its ITIM. Finally, we show that TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytoxicity thus providing an ''alternative self'' mechanism for MHC class I inhibition.
inhibitory receptors ͉ natural killers I n contrast to T cells, that possess a single dominant antigen receptor (1) , NK cells rely on a vast combinatorial array of receptors to initiate effector functions (2) . Both activating and inhibitory receptors expressed on NK cells regulate their activity when interacting with tumors, virus infected cells and bacteria, as well as normal self-cells (2) . MHC class I-expressing cells are protected from NK-mediated lysis due to the recognition of various MHC class I proteins by the inhibitory receptors KIR, LIR and CD94-NKG2A (3). Other NK inhibitory receptors which do not interact with MHC class I also exist, such as CEACAM1 and IRp60 (4) (5) (6) (7) (8) . The significance, however, of these non-MHC class I inhibitory receptors in normal conditions is still unclear. All of the inhibitory receptors share a common immune receptor tyrosinebased inhibitory motif (ITIM) in their cytoplasmic regions, which delivers the inhibitory signal (3) .
The NK cell-mediated killing is extracted by specific receptors, among which are the natural cytotoxicity receptors (NCRs), which include the NKp30 that interacts with pp65 of human cytomegalovirus (CMV), BAT3 and the recently identified B7-family member B7-H6 (9) (10) (11) , and the NKp46/NKp44 receptors, which interact with various viral hemagglutinins (12, 13) . The NKG2D receptor interacts with MICA, MICB and ULBP 1-5 (14) and NKp80 interacts with AICL (15) . In addition, two other receptors, DNAM-1 and CD96, enhance NK cytotoxicity (16, 17) . Both DNAM-1 and CD96 recognize PVR (CD155), whereas DNAM-1 also recognizes PVRL2 (CD112) (16, 17) . It was recently shown that a new receptor, named TIGIT, for T cell Ig and ITIM domain, interacts with PVR and its related proteins and that TIGIT inhibits T cell activity indirectly through the manipulation of DC activity (18) . Here, we show that TIGIT, through its ITIM, can directly inhibit NK cytotoxicity.
Results

TIGIT Inhibits YTS Killing Through Its ITIM Motif.
While searching for new CD28 family-like receptors, based on bioinformatics analysis, we observed that a protein named VSIG9 or VSTM3 in the databases expresses an ITIM motif. We continued to work on this protein and found that it interacts with PVR (CD155) but not with any other NK ligands tested (supporting information (SI) Figs. S1 and S2). At the same time, Yu et al. (18) identified the same protein and named it TIGIT. Because we observed that TIGIT is found on all NK cells and because it also contains an ITIM motif, we continued our analysis concentrating on the function of TIGIT in NK cells.
To investigate TIGIT role in controlling NK activity, we initially generated anti-TIGIT mAbs. For that purpose, we used the human YTS NK cell line and transduced it with a lentivirus containing TIGIT fused to an HA tag in its extracellular domain, to allow its detection on the cell surface (Fig. 1A ). Mice were injected with the TIGIT-Ig fusion protein (described in Figs. S1 and S2) and hybridomas supernatants were tested for specific recognition of the YTS/TIGIT transfectants. Seven different mAbs were obtained that recognized YTS/TIGIT but not the parental YTS cells (Fig.  1 A) in moderate (mAb 1-3) and high (mAb 4-7) modes of recognition.
To test whether TIGIT could directly inhibit NK cell cytotoxicity, we evaluated the killing of YTS and YTS/TIGIT-HA cells. Because YTS cells manifest a restricted killing toward 721.221 cells which is mediated mainly through the interaction between the 2B4 receptor on YTS cells and its ligand, CD48, on the target cells (19) , it was important to demonstrate, as shown in Fig. S3 , that 2B4 is expressed at equal levels on the parental YTS/eco and on YTS/TIGIT cells. In addition, to allow the examination of TIGIT activity on NK cells we expressed PVR in 721.221 cells and demonstrated that it is indeed recognized by the anti-PVR mAb and by the TIGIT-Ig (Fig.  S3) . Finally, we verified that CD48 is present in equal levels on all 721.221 cells (Fig. S3) . All of these reagents were used in killing assays and as demonstrated in Fig. 1B a strong inhibition of YTS/TIGIT killing is observed when PVR is expressed on 721.221 cells and this inhibition could be blocked with mAb #4. The increased killing observed with mAb #4 was due to blockage of TIGIT and not due to ADCC, because 721.221 cells do not express Fc receptors.
It was shown that the ITIM of the inhibitory receptors is critical for their inhibitory activity (20, 21) . To test whether the ITIM of TIGIT is responsible for its inhibitory activity, we generated a truncated form of the TIGIT receptor at position 231 in the ITIM motif (named Y231stop) and also a point mutation in the 231 tyrosine reside mutating it into alanine (named Y231A). These TIGIT proteins were expressed in YTS cells, and in addition, we generated control-transfected YTS cells expressing GFP. Expression levels of all TIGIT proteins were similar. The various YTS transfectants were next assayed for killing of 721.221 and 721.221/ PVR cells. Importantly, although a strong PVR-mediated inhibition was observed with YTS/TIGIT, no major difference in the killing of 721.221 and 721.221/PVR was noticed when the control YTS/GFP, YTS/TIGIT Y231stop and YTS/TIGIT Y231A were used (Fig. 2) . Thus TIGIT is a direct inhibitory receptor for NK cells and its inhibitory activity is depending on its ITIM. Biochemical Characterization of TIGIT. Next, we used our YTS transfectants for biochemical analysis of TIGIT and immunoprecipitated TIGIT from YTS/TIGIT-HA cells by using anti-HA-agarose beads, followed by immunobloting with anti-HA antibodies. Two protein bands in sizes of Ϸ30 and 34 kDa, probably representing different glycosylation forms of TIGIT, were noticed in the YTS/ TIGIT and in the YTS/TIGIT Y231A cells, whereas, as expected, lower-weight protein bands were observed in the YTS/TIGIT Y231stop cells (Fig. 3A) . To further strengthen our analysis, we used a specific mouse anti-TIGIT Ab for the immunoprecipitation and again detected these two main protein products only in YTS/TIGIT and not in YTS/eco cells. These products were approximately the same size as observed above (Fig. 3B) .
TIGIT Function on Primary Immune Cells. We next analyzed TIGIT expression on various immune cells by using our anti-TIGIT mAbs and observed that TIGIT is expressed on NK, NKT, CD8 ϩ , Treg, and memory CD4 ϩ T cells (Fig. 4A ). Because it was previously shown that PVR is also a ligand for the receptors DNAM-1 and CD96 (16, 17) , we determined the expression and function of all three PVR-binding receptors on NK cells. We initially evaluated their expression on freshly isolated and on IL-2 activated bulk NK cells, and the expression of all of the PVR-binding receptors did not significantly change after IL-2 activation, as can be seen in Fig. 4B . Next, we performed a redirected killing assay to address the direct function of each of the three PVR-binding receptors on NK cells. As shown in Fig. 4C , both DNAM-1 and CD96 failed to independently redirect NK cytotoxicity, whereas, in contrast, direct cytotoxicity was induced by 2B4 and NKp30 (Fig. 4C) . Thus, in agreement with previous publications (22) , DNAM-1 and CD96 are coactivating receptors. On the other hand, TIGIT was shown to be an inhibitory receptor on NK cells, as the redirected killing of the IL-2 activated bulk NK cultures induced by anti-2B4 or anti-NKp30 mAbs was inhibited by cross-linking of TIGIT with anti-TIGIT mAb #4 (Fig. 4D) .
Next, we studied the TIGIT activity as part of the complex killing machinery of NK cells when encountering tumor cells expressing PVR. IL-2-activated bulk NK cell cultures were incubated with 721.221 and 721.221/PVR, and, as demonstrated in Fig. 4E , the killing of 721.221/PVR was only slightly induced, indicating that the PVR-CD96/DNAM-1 interactions are too weak in the context of 721.221/PVR cells to strongly up-regulate NK cytotoxicity. Importantly, blocking TIGIT-PVR interaction by mAb #4 and #5, but not with #1 (which did not bind the NK cells, Fig. S4 ), resulted in a significantly increased killing of the PVR expressing 721.221 cells, indicating that TIGIT inhibition is indeed dominant over the coactivation of CD96 and DNAM-1. Finally, we tested the functional relevance of the PVR-like proteins-TIGIT interactions by using the YTS/TIGIT and YTS/ TIGIT Y231stop cells. As seen in Fig. 5C , whereas PVR showed the strongest inhibition, the inhibition mediated by PVRL2 was less efficient, and no inhibition was observed when PVRL3, was used (Fig. 5C ). The inhibition was ITIM dependent because no inhibition was observed when YTS/TIGIT Y231stop (Fig. 5C ) cells were used. Thus, these combined results indicate that PVRL2 is a low-affinity ligand for TIGIT as compared with PVR, whereas PVRL3 is not a ligand for TIGIT.
TIGIT Provides an ''Alternative Self'' Mechanism for MHC Class I Inhibition. The expression of PVR and PVRL2 is up-regulated on tumor cells (16, 23) , and thus it was logical to assume that the interactions of PVR and PVRL2 with their coactivating receptors will lead to enhanced tumor killing. On the other hand, PVR and PVRL2 are widely expressed on healthy normal cell types of epithelial origin and on peripheral blood monocytes (24, 25) and it is of course undesirable for NK cells to kill these normal cells. We therefore hypothesized that the inhibitory interactions of TIGIT would be dominant over the coactivating ones of DNAM-1 and CD96 to prevent self killing. For that purpose, we used the primary human foreskin fibroblasts cells which endogenously express PVR, PVRL2 and PVRL3 (Fig. 6A Upper) and also MHC class I, detected by KIR2DL1-Ig and LIR1-Ig (Fig. 6A Lower) and incubated them with bulk NK cell cultures. No staining of the fibroblasts cells was observed with KIR2DL2-Ig, indicating that the fibroblasts we used from this particular infant do not expressed HLA-C proteins characterized by the presence of the asparagine residue at position 80. As can be seen in Fig. 6B , the killing of the fibroblasts cells was low even when MHC class I proteins were blocked by the fusion proteins or when TIGIT was blocked by the anti-TIGIT mAb. Importantly, however, when both MHC class I and TIGIT were blocked (by the KIR2DL1-Ig and LIR1-Ig fusion proteins and anti-TIGIT mAb, respectively), a significant killing was induced (Fig. 6B) . Thus, TIGIT is an inhibitory receptor which prevents killing of self-normal cells by NK cells.
Discussion
The current manuscript, together with the findings of Yu et al. (18) , place TIGIT as a vital immunomodulator protein, able to control the activities of both NK and T cells.
In NK cells, the inhibitory signal of TIGIT is mediated via its ITIM. In addition, as TIGIT binds PVR with the highest affinity compared with DNAM-1 and CD96 (18) , TIGIT should also physically interfere with DNAM-1 and CD96 binding. We still do not know why, in T cells, TIGIT is not a direct inhibitory receptor (18) . However, it seems as if the inhibitory activity of TIGIT might be different from other NK inhibitory receptors as we could not precipitate TIGIT under nonreducing conditions (suggesting that it might be found in complexes) and we could not precipitate SHP1 with TIGIT.
In agreement with Yu et al. data, we also observed that TIGIT interacts with PVRL2 and that this interaction leads to the inhibition of NK cell cytotoxicity. Surprisingly, and in contrast to Yu et al . data, we demonstrate in our systems that TIGIT bind PVRL3, even when using transfectants expressing high levels of PVRL3. We currently have no explanation for this discrepancy but since we used several systems, including functional assays, we think that the PVRL3-TIGIT interactions, if exist, are not functional.
Remarkably, two additional coactivating receptors expressed on NK and T cells, DNAM-1 and CD96, also bind PVR, and DNAM-1 shares another ligand with TIGIT, PVRL2 (16, 17) . This situation is a reminiscent of T cells, in which the coinhibitory receptor CTLA-4 binds the same ligands (B7-1 and B7-2) as the coactivating receptor CD28 (26) (27) (28) (29) . This apparent conflict is resolved in T cells due to the fact that expression of CTLA-4 is increased after T cell activation (30) . In addition, CTLA-4 binds its ligands in a much higher affinity than CD28, resulting in the inhibition of T cell functions (27) . Another example for pairwise receptors is the killer Ig-like receptor (KIR) family (31) that also includes activating counterparts named KARs (32) . Currently, few KARs share the same MHC class I ligands as the KIR (33), but they interact with the appropriate MHC class I proteins with lower affinity (34, 35) . Thus, in both CTLA-4/CD28 and KIR/KAR pairs, inhibition is dominant and as we and Yu et al. (18) show by functional and by binding assays, the TIGIT-PVR interaction is dominant over that of CD96/DNAM1-PVR.
Interestingly, staining 721.221 transfectants with TIGIT-Ig and with DNAM1-Ig, unexpectedly demonstrated weak binding of DNAM1-Ig to 721.221 cells expressing PVRL3, suggesting that PVRL3 might be an additional ligand for DNAM-1. Thus, the PVR-binding receptors might be balanced not only by the strength of their binding but also by the variegated expression of their ligands.
In the original paper describing DNAM-1-PVR interaction (19) , PVR blockade resulted in a strong reduction of cytolysis by DNAM-1-expressing YT cells. Here, we used the YT derivative YTS and, surprisingly, observed no increase in the killing of 721.221/PVR cells by the parental YTS cells. To resolve this discrepancy, we stained YTS cells with an anti-DNAM-1 antibody and, surprisingly, observed that indeed YTS cells express DNAM-1 (Fig. S5) . However, when we stained YTS cells with PVR-Ig, no binding was observed, whereas YTS/TIGIT cells were recognized by PVR-Ig (Fig. S5) . Thus, it seems as if, although DNAM-1 is expressed on YTS cells, for an as yet unknown reason, it cannot interact with PVR.
As we show here, TIGIT is an inhibitory receptor expressed by all NK cells and PVR, PVRL2 and even PVRL3 are expressed on normal cells of an epithelial origin, such as endothelial cells. Endothelial cells are continuously encountered by NK cells when, for example, NK cells extravasate to the tissues. Thus, we suggest that under normal conditions, PVR and PVRL2 provide an alternative self mechanism preventing self destruction of normal cells by NK cells.
Interestingly, enhanced expression of PVR and PVRL2 is also observed in various tumors (16, 23, 36) and several recent reports demonstrated that PVR and PVRL2 expression on tumors might enhance NK cytotoxicity (37) (38) (39) (40) . Furthermore, it was recently demonstrated that knockout of DNAM-1 resulted in enhanced tumorgenicity (22, 41) . In light of our observations, we think that these previous works should be reevaluated as it seems as if the function of PVR and PVRL2 on tumor cells is not to be better recognized by NK killer and inhibitory receptors, but maybe, as suggested previously to aid tumor invasion and migration (36) .
Materials and Methods
Cells and Transfectants. The cell lines used in the present study were YTS cells, transfected with the ecotropic murine retrovirus receptor (YTS/eco), the human EBV-transformed B-cell line 721.221, 721.221 transfectants (33), the mastocytoma cell line P815 and P815 stably expressing PVR (a kind gift from M. Colonna, Washington University.) and the murine thymoma BW cell line. Human fibroblasts were obtained from primary cultures of foreskins. NK cells were isolated from peripheral blood lymphocyte samples.
Antibodies. The mAbs used in this work were anti-CD155/PVR clone 300907 (R&D Systems), anti-PVRL2/CD112 clone TX31 (BioLegend), anti-PVRL3/CD113 clone N3.12.4 (Santa Cruz Biotechnology), 12E7 directed against CD99 (used as an isotype control, was a gift from A. Bernard, INSERM, France), 12CA5 directed against HA, anti-2B4 clone C1.7 (Beckman-Coulter), anti-NKp30 clone 210845 (R&D Systems), and anti-DNAM-1 clone 102511 (R&D Systems).
BW Assay and Cytotoxicity Assay.
For measurement of IL-2 production resulting from the interaction between TIGIT and the PVR-family proteins, we used the BW 
SI Text
Generation of Fusion Proteins. The coding sequence of TIGIT was cloned as a fusion to the Fc fragment of IgG1 to generate the recombinant Fc-fused protein. The C-terminal Gln of TIGIT at amino acid 139 position of the TIGIT was fused to the heavy chain hinge of a deglycosyltaed Fc (N297A), followed by the CH2 and CH3 regions. The ORF of the recombinant protein was codon optimized for high-level expression in mammalian cells. The optimized DNA sequence was synthetically synthesized by GeneArt with the addition of flanking DNA sequences corresponding to EcoRI and NotI restriction sites at the 5Ј and 3Ј ends of the DNA fragment, respectively. The expression vector was constructed by double digestion of the optimized DNA fragment with EcoRI and NotI, followed by its ligation into pIRESpuro3 (Clontech Laboratories, Inc.). For the production of DNAM-1-Ig fusion protein, the sequence encoding the extracellular portion of DNAM-1 was amplified by PCR using the 5Ј primer CCGATATCGCCGCCACCATGGATTATCCTACTTTACT-TTTG (including EcoRV restriction site) and the 3Ј primer CGGATCCACAAAGAGGGTATATTGGTTAT (including BamHI restriction site). This PCR-generated fragment was cloned into the expression vector containing the mutated Fc portion of human IgG1 (Fc mut pIRESpuro3) .
The resulting constructs were transfected into HEK-293T cells by using the FuGENE 6 Transfection Reagent (Roche Diagnostics). After 48 h, transfected cells were subjected to antibiotic selection with 5 g/mL puromycin (Sigma-Aldrich). Stable pools were analyzed for protein secretion by SDS/PAGE. Supernatants were collected and purified on a Poros 20 protein G column in the High Pressure Perfusion Chromatography Station, BioCAD (PerSeptive Biosystems).
Generation of Transfectants.
For the generation of 721.221 cells expressing PVR, the PVR cDNA was amplified by PCR using the 5Ј primer CCCAAGCTTGCCGCCACCATGGCCGC-CGCGTGGC (including HindIII restriction site) and the 3Ј primer GGTCTAGATCACCTTGTGCCCTCTGTCTG (including XbaI restriction site). For the generation of 721.221 cells expressing PVRL2, the PVRL2 cDNA was amplified by PCR by using the 5Ј primer CCCAAGCTTGCCGCCACCATGGCCCGGGCCGC-TGCC (including HindIII restriction site) and the 3Ј primer CG-GGCCCTCACACATACATGGCCCGGGA (including ApaI restriction site). For the generation of 721.221 cells expressing PVRL3, the PVRL3 cDNA was amplified by PCR using the 5Ј primer TATAAGCTTGCCACCATGGCGCGGACCCTGCGG (including HindIII restriction site) and the 3Ј primer GGTCTAGACTA-AACATACCACTCCCTCCTG (including XbaI restriction site). The PVR, PVRL2 and PVRL3 constructs were cloned into pc-DNA3 vector (Invitrogen Life Technologies) and was stably expressed in 721.221 cells.
For the generation of BW cells expressing the chimeric TIGITprotein, the extracellular portion of the human TIGIT protein was amplified by PCR from cDNA isolated from peripheral blood lymphocytes using the 5Ј primer CGAATTCGCCGCCACCAT-GCGCTGGTGTCTCCTCC (including EcoRI restriction site) and the 3Ј primer TCCATCTAGCAAGTAGCAGAGTGGAATCT-GGAACCTGGCACC (including the first twenty one nucleotides of the mouse -chain transmembrane portion). The mouse -chain was amplified by PCR using the 5Ј primer GGTGCCAGGTTC-CAGATTCCACTCTGCTACTTGCTAGATGGAA (including last twenty one nucleotides of human TIGIT extracellular portion) and the 3Ј primer CCGAATTCTTAGCGAGGGGCCAGGG-TCTG (including XbaI restriction site). The two amplified fragments were mixed, and PCR was performed with the 5Ј EcoRI primer and the 3Ј XbaI primer for generation of the TIGITconstruct. The TIGIT-construct was cloned into pcDNA3 expression vector (Invitrogen Life Technologies) and was stably expressed in BW cells.
For the generation of YTS NK tumor line expressing TIGIT fused to an HA tag the signal peptide of TIGIT was amplified by PCR using the 5Ј primer CGGATCCGCCGCCACCATGCGCT-GGTGTCTCCTCC (including BamHI restriction site) and the 3Ј primer AGCGTAATCTGGAACATCGTATGGGTAGGGAG-CCTGCCTCAGCCC (including the twenty seven nucleotides coding for the HA tag). TIGIT was amplified by PCR using the 5Ј primer TACCCATACGATGTTCCAGATTACGCTCTCGCCT-CAGGAATGATGACA (including the 27 nucleotides coding for the HA tag) and the 3Ј primer CCTGTACACTAACCAGTCTC-TGTGAAGAAG (including Bsp1407 restriction site). The two amplified fragments were mixed, and PCR was performed with the 5Ј BamHI primer and the 3Ј Bsp1407 primer for the generation of the TIGIT-HA construct.
For generation of the TIGIT protein mutated in Y231A, we used the TIGIT-HA construct as a template and amplified by PCR the 3Ј end of the gene by using an internal 5Ј primer GTCCTGAGT-GCCAGAAGCCT bearing the mutation and the gene-specific 3Ј-edge primer (including the Bsp1407 restriction site). The PCR product was used as a 3Ј primer together with the gene-specific 5Ј-edge primer (including the BamHI restriction site) for the generation of the mutated full-gene cDNA.
The TIGIT-HA and the two mutated constructs were then cloned into the lentiviral vector SIN18-pRLL-hEFI␣p-EGFP-WRPE (1), instead of the GFP coding sequence. Lentiviral viruses were produced by transient three-plasmid transfection as described (2) . These viruses were used to transduce YTS cells in the presence of polybrene (6 g/mL). All transfectants were periodically monitored for expression by staining with the appropriate mAb.
ELISA. Ninety-six-well dishes were coated with 25 ng of protein per well in 100 mM sodium carbonate buffer, washed and blocked with 5% milk in PBS. 50 L of hybridoma culture supernatant was applied for 1 h at room temperature. Plates were washed with sodium carbonate buffer and then incubated with alkaline phosphataseconjugated goat anti-mouse IgG (Sigma). Plates were washed and incubated with 100 L of 1 mg/mL p-nitrophenyl phosphate disodium (PNPP) (Sigma). Positives clones were further confirmed by staining of BW/TIGIT-and YTS/TIGIT-HA.
Flow Cytometry. Cells were stained with either mAbs or Ig fusion proteins as previously described (1).
BW Assay. Fifty thousand BW or BW-transfected cells were incubated in RPMI medium (Sigma-Aldrich) plus 10% FCS with 50,000 irradiated (3,000 rad) target cells as indicated in the figure for 48 h at 37°C and 5% CO 2 . Supernatants were collected, and the level of IL-2 was quantified by using anti-IL-2 mAb and standard ELISA (BD PharMingen). Counts anti-TIGIT #7 anti-TIGIT #6 anti-TIGIT #5 anti-TIGIT #4 anti-TIGIT #3 anti-TIGIT #2 Fig. S4 . Binding of the various anti-TIGIT mAbs to primary NK cells. FACS analysis of IL-2 activated bulk NK cell cultures stained with seven different antibodies directed against TIGIT. Gray shaded histograms, background staining with the secondary fluorescein-conjugated antibody only. Mouse antibodies #4-7, which recognized TIGIT in the highest affinity (Fig. 1A) , also recognized TIGIT on IL-2-activated bulk NK cells. 
